Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+,
HER2- Advanced or Metastatic Breast Cancer (mBC)
Contenuto disponibile solo in lingua inglese